These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 10869954)
1. Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors. Amato RJ; Prow DM Urol Oncol; 2000 Jul; 5(4):134-138. PubMed ID: 10869954 [TBL] [Abstract][Full Text] [Related]
2. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors. Bokemeyer C Oncology; 1998; 55(3):177-88. PubMed ID: 9560052 [TBL] [Abstract][Full Text] [Related]
3. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer]. Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143 [TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340 [TBL] [Abstract][Full Text] [Related]
6. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262 [TBL] [Abstract][Full Text] [Related]
7. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors. Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104 [TBL] [Abstract][Full Text] [Related]
8. Recent strategies for the use of paclitaxel in the treatment of urological malignancies. Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Kollmannsberger C; Beyer J; Jonas U; Kanz L World J Urol; 1998; 16(2):155-62. PubMed ID: 12073232 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648 [TBL] [Abstract][Full Text] [Related]
10. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. Kollmannsberger C; Mayer F; Kuczyk M; Kanz L; Bokemeyer C World J Urol; 2001 Apr; 19(2):120-5. PubMed ID: 11374314 [TBL] [Abstract][Full Text] [Related]
13. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059 [TBL] [Abstract][Full Text] [Related]
16. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198 [TBL] [Abstract][Full Text] [Related]
17. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558 [TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors. Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945 [TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. Hartmann JT; Einhorn L; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Bokemeyer C J Clin Oncol; 2001 Mar; 19(6):1641-8. PubMed ID: 11250992 [TBL] [Abstract][Full Text] [Related]
20. A phase II trial of paclitaxel in refractory germ cell tumors. Sandler AB; Cristou A; Fox S; Williams SD; Nichols CR; Turns M; Roth BJ Cancer; 1998 Apr; 82(7):1381-6. PubMed ID: 9529032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]